Posted by Michael Wonder on 19 Mar 2021
NICE rejects Keytruda for advanced bladder cancer in final guidance
18 March 2021 - The UK’s NICE has issued a second final appraisal document rejecting MSD’s Keytruda for the treatment of advanced bladder cancer.
MSD had initially been granted authorisation for Keytruda (pembrolizumab) in advanced or metastatic urothelial carcinoma patients who had previously received platinum-based chemotherapy via NICE’s Cancer Drugs Fund in 2018.
